Multiple preclinical studies have shown these synergistic antitumor activities of dual blocking of PI3K and PARP in breast cancer, prostate cancer, and ovarian cancer regardless of PIK3CA or BRCA mutational status, which broadens the indications of PARP inhibitors.40, 41, 42. This evidence concerns the gene PIK3CA and prostate carcinoma.